Related Experiment Video

Updated: Jul 17, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Improving outcomes in chronic heart failure

Michel Komajda1

  • 1Institut de Cardiologie, Hopital Pitie-Salpetriere, Universite Pierre et Marie Curie, Paris, France.

Drugs of Today (Barcelona, Spain : 1998)
|January 25, 2007
PubMed

Insights

Angiotensin receptor blockers (ARBs) like candesartan significantly reduce cardiovascular death and heart failure hospitalizations in patients. ARBs also lower the risk of new-onset diabetes and atrial fibrillation.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Recent trials of angiotensin receptor blockers (ARBs) necessitate updates to European Society of Cardiology chronic heart failure management guidelines.
  • The CHARM program's trials are pivotal in evaluating ARBs, specifically candesartan, in heart failure patients.

Purpose of the Study:

  • To assess the efficacy of candesartan in managing chronic heart failure across different patient subgroups.
  • To evaluate the impact of candesartan on cardiovascular outcomes, new-onset diabetes, and atrial fibrillation.

Main Methods:

  • The study analyzed data from three CHARM program trials (CHARM-Alternative, CHARM-Added, CHARM-Preserved) comparing candesartan to placebo.
  • Patients included those intolerant to ACE inhibitors, those on ACE inhibitors, and those with preserved ejection fraction.

Main Results:

  • Candesartan significantly reduced cardiovascular death or heart failure hospitalization in patients intolerant to ACE inhibitors (CHARM-Alternative).
  • This risk reduction was also significant in patients already on ACE inhibitors (CHARM-Added).
  • A borderline significant risk reduction was observed in patients with preserved ejection fraction (CHARM-Preserved). Candesartan also reduced new-onset diabetes and atrial fibrillation risk (CHARM-Overall).

Conclusions:

  • Candesartan is effective in reducing adverse cardiovascular events in various chronic heart failure populations.
  • The findings support the use of ARBs, specifically candesartan, in updating heart failure treatment guidelines.
  • Candesartan demonstrates broader benefits, including reduced incidence of new-onset diabetes and atrial fibrillation.

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...